This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, W. Articles by Tsuruo, T. Search for Related Content PubMed PubMed Citation Articles by Sato, W. Articles by Tsuruo, T.

Circumvention of Multidrug Resistance by a Newly Synthesized Quinoline Derivative, MS-073¹

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170 [W. S., K. Y., T. T.], Institute of Biological Science, Mitsui Pharmaceuticals Inc., Mobara, Chiba 297 [W. S.], Life Science Laboratory, Mitsui, Toatsu Chemicals Inc., Mobara, Chiba 297 [N. F., T. S.], and Institute of Applied Microbiology, University of Tokyo, Tayoi, Bunkyo-ku, Tokyo 113 [T. T.], Japan

Newly synthesized quinoline derivatives were investigated for their efficacy to reverse multidrug resistance (MDR). In this study, one of the most effective quinoline derivatives, MS-073, was compared with verapamil with regard to its ability to overcome MDR in vitro and in vivo. MS-073 at 0.1 µM almost completely reversed in vitro resistance to vincristine (VCR) in VCR-resistant P388 cells. The compound also reversed in vitro VCR, adriamycin (ADM), etoposide, and actinomycin D resistance in ADM-resistant human myelogenous leukemia K562 (K562/ADM) cells, ADM-resistant human ovarian carcinoma A2780 cells, and colchicine-resistant human KB cells. MS-073 administered i.p. daily for 5 days with VCR enhanced the chemotherapeutic effect of VCR in VCR-resistant P388-bearing mice. Increases in life span of 19–50% were obtained by the combination of 100 µg/kg of VCR with 3–100 mg/kg of MS-073, as compared to the control. The ability of MS-073 to reverse MDR was remarkably higher, especially at low MS-073 doses, than that of verapamil, both in vitro and in vivo.

MS-073 enhanced accumulation of [³H]VCR in K562/ADM cells. Photolabeling of P-glycoprotein with 200 nM [³H]azidopine in K562/ADM plasma membranes was completely inhibited by 10 µM MS-073, indicating that MS-073 reverses MDR by competitively inhibiting drug binding to P-glycoprotein.

¹ This work was supported by grants from the Ministry of Education, Science and Culture, Japan.

² To whom requests for reprints should be addressed.

Received 11/ 2/90. Accepted 2/13/91.

This article has been cited by other articles:

				A. Sandler, M. Gordon, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, A. Chaudhary, K. Fife, L. Battiato, C. Sweeney, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy Clin. Cancer Res., May 15, 2004; 10(10): 3265 - 3272. [Abstract] [Full Text] [PDF]

				E. H. Rubin, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, Y. Lin, R. Musanti, S. L. Grospe, S. L. Smith, D. L. Toppmeyer, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies Clin. Cancer Res., December 1, 2002; 8(12): 3710 - 3717. [Abstract] [Full Text] [PDF]

				E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson The Farnesyl Protein Transferase Inhibitor SCH66336 Is a Potent Inhibitor of MDR1 Product P-glycoprotein Cancer Res., October 1, 2001; 61(20): 7525 - 7529. [Abstract] [Full Text] [PDF]

				B. J. Smith, A. C. Doran, S. McLean, F. D. Tingley III, B. T. O'Neill, and S. M. Kajiji P-Glycoprotein Efflux at the Blood-Brain Barrier Mediates Differences in Brain Disposition and Pharmacodynamics between Two Structurally Related Neurokinin-1 Receptor Antagonists J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1252 - 1259. [Abstract] [Full Text] [PDF]

				E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson In Vitro Flow Cytometry Method to Quantitatively Assess Inhibitors of P-Glycoprotein Drug Metab. Dispos., May 1, 2000; 28(5): 522 - 528. [Abstract] [Full Text]

				H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines J. Bone Joint Surg. Am., March 1, 1996; 78(3): 366 - 75. [Abstract] [Full Text]